Optimizing Hepatitis C Treatment Monitoring: Is Sustained Virologic Response at 4 Weeks Becoming the New Standard?

Area of Science:

• Hepatology
• Virology
• Clinical Medicine

Background:

• Chronic hepatitis C (HCV) infection remains a global health challenge.
• Effective treatment monitoring is crucial for achieving sustained virological response (SVR).
• Current guidelines often recommend 12 weeks post-therapy for SVR assessment.

Purpose of the Study:

• To evaluate the predictive values, sensitivity, and specificity of a 4-week SVR assessment compared to the standard 12-week assessment.
• To identify predictors of achieving SVR at both 4 and 12 weeks post-therapy.
• To explore the potential for shortening the HCV treatment monitoring period.

Main Methods:

• A study involving 216 patients with chronic hepatitis C at two infectious disease clinics.
• Analysis of predictive values, sensitivity, and specificity for 4-week vs. 12-week SVR.
• Identification of independent predictors for SVR achievement.

Main Results:

• High sensitivity (100%) for predicting 12-week SVR based on 4-week SVR across most genotypes.
• Specificity of 75% for genotype 1b treated with EBR/GZR therapy at 4 weeks.
• Younger age and less advanced liver fibrosis were independent predictors of SVR.
• Biochemical parameters normalized post-treatment, indicating improved liver function.

Conclusions:

• A 4-week SVR assessment may be a viable option for specific patient groups (younger, no significant fibrosis).
• Shortening the monitoring period could reduce loss to follow-up and align with 'test and treat' strategies.
• Further research and guideline incorporation are needed to validate and implement a 4-week SVR assessment.